Pirtobrutinib is not yet approved and available in the EU and UK. But doesn't mean you can't access it immediately. Read on for all your options.
Blog
-
October 17, 2023
-
October 16, 2023
Belzutifan is currently approved as an orphan medicine in the UK. Find out when it will be widely available on the market, and what that means for you.
-
October 10, 2023
Everything you should know about Enhertu in the UK. What is it approved for, and how can you access it?
-
October 03, 2023
How effective is Enhertu for ovarian cancer, and can your doctor prescribe it before it's approved for this indication? All the answers - here.
-
October 03, 2023
What happens after Adakveo's revocation in the EU? Understand the reasons for the EMA's decision, and the Adakveo alternatives you have.
-
September 27, 2023
Find out the key similarities and differences between Adakveo and Oxbryta, including how to access both medicines.
-
September 25, 2023
When will dostarlimab be available in Belgium? Find out all the ways to access it in the meantime.
-
September 25, 2023
When will dostarlimab be available in the UK? Learn everything worth knowing about accessing the medicine.
-
September 25, 2023
Why teclistamab isn't available in Germany (yet) and how to access it in the meantime.
-
September 13, 2023
What types of cancer can dostarlimab treat? See all the latest approvals and research about this novel cancer treatment.
-
September 04, 2023
A simple overview of Jemperli and Keytruda as treatment options for endometrial cancer. Find out how they work, how efficient they are, and how much they cost.
-
August 29, 2023
Is it possible to combine Dupixent with Opzelura in your eczema treatment? All your questioned answered.
-
August 29, 2023
Everything you and your doctor should know about the potential usage od Opzelura for psoriasis.
-
August 22, 2023
All vitiligo patients in the UK should know about Opzelura avaiability on the market, and the alternatives in the meantime.
-
August 22, 2023
Understand the similarities and differences between Briumvi, Ocrevus and Kesimpta in one simple overview.
-
August 22, 2023
Can you use Jakavi for your vitiligo, while waiting for Opzelura to become available on the European market? All you need to know.
-
August 22, 2023
Is it possible to get a Leqembi home infusion? Will you be able to inject Leqembi at home by yourself soon? Learn all we know.
-
August 03, 2023
The difference between Leqembi and Aduhelm, simply explained. How do these Alzheimer's medicines work, where are they approved, and how can you access them?
-
August 02, 2023
How nitisinone tablets give hope to HT-1 and AKU patients. Now also available for free in India, Pakistan, Bangladesh and Sudan.
-
July 14, 2023
Find hope and support with Alzheimer's treatment options. Learn about innovative therapies and resources to manage symptoms and improve quality of life.
-
July 14, 2023
Everything you need to know about Briumvi, the latest approved CD20 antibody for the treatment of multiple sclerosis.
-
June 26, 2023
Anti-amyloid therapy for Alzheimer's, explained simply. What is it, how does it work, which one is approved, and how can you access it?
-
June 26, 2023
All the safe and legal options to access Leqembi while it's waiting for its EU approval.
-
June 26, 2023
All you need to know about Leqembi, the latest approved Alzheimer's medicine.
-
June 16, 2023
A simple overview of standard and emerging NSCLC treatments.
-
June 16, 2023
Understanding KRAS inhibitors for lung cancer: how they work, which ones are approved, and what's coming?
-
June 16, 2023
Sotorasib vs Adagrasib: A side-by-side comparison of the latest Alzheimer's medicines.
-
Anti-amyloid therapy for Alzheimer's, explained simply. What is it, how does it work, which one is approved, and how can you access it?
-
June 17, 2022
The Medicine Access Masterclass is a unique overview of early medicine access options of innovative medicine which cannot be found anywhere else.
-
November 29, 2021
Paxlovid is an antiviral administered orally to patients who are ill with COVID-19 or have been exposed to the coronavirus SARS-CoV-2 and are at risk of developing severe illness. The manufacturer, pharmaceutical and biotechnology giant Pfizer, developed it to patients avoid severe illness which can lead to hospitalization and death. It is meant to be administered at the first sign of infection.